FDA Considers Expanding Keytruda Use for Advanced Melanoma

Article

The FDA is considering expanding the use of Merck's pembrolizumab as a first-line treatment for advanced melanoma.

The FDA is considering expanding the use of Merck’s pembrolizumab (Keytruda) as a first-line treatment for advanced melanoma.

Keytruda has received Priority Review for this new indication from the FDA, which is now expected to make its approval decision on December 19, 2015.

The supplemental Biologics License Application (sBLA) for Keytruda as a first-line treatment for unresectable or metastatic melanoma patients was partially based on data from the phase 3 KEYNOTE-006 trial, which evaluated the drug in 834 patients.

Keytruda is currently approved at a dose of 2 mg/kg infused over 30 minutes every 3 weeks in patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, for those who are BRAF V600 mutation positive, a BRAF inhibitor.

The FDA has also extended its action date for a separate Keytruda sBLA for the treatment of patients with ipilimumab-refractory advanced melanoma to December 24, 2015.

Related Videos
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.